Agent for treatment of eye disease

FIELD: medicine, ophthalmology, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to design of ophthalmological agents of broad spectrum based on vegetable components, vitamins and trace elements. Agent for treatment of eye diseases comprises bilberry berries of sublimation drying, dihydroquercetin, beta-carotene, selexen, lutein, vitamins B1, B2, B6, B12 and zinc. Agent shows the effect of broad spectrum and possesses regenerating, tonic and regenerative effect being without irritating, allergizing, inflammatory and other undesirable effects, and excluding mechanical contact with eye surface.

EFFECT: valuable medicinal properties of agent.

5 cl

 

The invention relates to chemical-pharmaceutical industry, namely to create eye means a wide spectrum of action on the basis of herbal ingredients, vitamins and trace elements.

Known drugs aimed at the treatment of certain eye diseases, are used, usually in the form of drops or ointments for external use.

Known ophthalmic drug for the treatment of various eye diseases based on an extract of brown algae (RF patent 2104679, 61F 9/00).

Known means of increasing visual acuity on the basis of the water decoction of dried berries of Chinese Magnolia vine, which is administered either in the conjunctival SAC as an external agent, or in the tissue of the eye by way of electrophoresis (ed. St. USSR 171981, AK 35/78).

Know the application for therapeutic purposes, the leaves and fruits of blueberries. It is established that in addition to a broad spectrum of action on the human body, the use of bilberry improves visual acuity, provides increased field of view, reduces eye fatigue without operation of the ocular surface without damaging the psyche of the person (Gaetan Jail "blueberry sight." TASS, Bulletin of foreign scientific and technical information TASS, 1964, 72 (962), 1964).

Set that is contained in the blueberry flavonoids (rutin, quercetin, vitamins) strengthen the walls of blood vessels and regulate their permeability.

It is also known that products with vitamin e is used to treat beriberi, hemorrhages in the retina, capillariasis to restore neuro-trophic processes in the cornea.

These drugs are aimed at improving visual functions. However, their use in the form of ointments, films or droplets involves mechanical contact with the surface of the eye and its injury. In addition, each of the known means inherent in the apparent orientation of the action.

At the same time there are cases when excessive exploitation of the surface of the eye, irritation and appropriate psychological trauma to the patient is extremely undesirable, and the impact on visual function, as necessary. To this end, apply a medicinal product that is inside the body orally in the form of tablets, capsules, fees, extracts.

The closest solution to the stated is biologically active additives (BAA) "Ophthalmologist", containing blackberries freeze-drying, dihydroquercetin, beta-carotene, selexin (TU 9197-028-17664661-05 FEZ 377.99.29.003 from 26.07.2005). This Supplement is recommended for retinopathy, night blindness, eye fatigue, glaucoma, cataracts.

The specified medication has a number of advantages compared with the known. Use inside excludes injury to the eye on top of the spine. However, its application is also directional in nature and does not possess prolonging effect.

The task of the invention is to create a wide spectrum of action for the treatment of diseases of the eye by creating a balanced complex of herbal ingredients, vitamins and trace elements.

The technical result consists in the fact that the claimed product has a regenerative, restorative and regenerative action, clean and devoid of irritant, allergic, inflammatory and other undesirable effects, avoiding mechanical contact with the surface of the eye and increase therapeutic effect, and can also be used as a vehicle for maintenance therapy in the pathology of yellow spots (macular degeneration), and the retina.

The problem is solved as follows.

The proposed remedy for the treatment of diseases of the eye, which in addition to blueberries freeze-drying, dihydroquercetin, beta-carotene and selexin additionally contains lutein, vitamin B1B2In6In12and zinc in the following ingredients per 1 capsule in mg:

of 17.0
blueberries freeze-drying282,7
dihydroquercetin
beta carotene0,23
selexin0,07
lutein0,75-20,0
vitamin B10,255-10,2
vitamin b2of 0.3 to 12.0
vitamin b6of 0.3 to 12.0
vitamin b120,45-18,0 mcg
zinc1,8-80,0

The tool can be used to improve vision in retinopathy, night blindness, eye fatigue, glaucoma, cataracts.

The tool can be used as a tool for maintenance therapy in the pathology of yellow spots (macular degeneration), and the retina.

The proposed tool is conventionally called "Eye-complex".

Get the tool by mixing the components in predetermined quantities and Packed in capsules.

Dose for prevention of the above diseases is 1 capsule 3 times a day during meals.

Dose as a means for supporting therapy is 2 capsules 3 times a day during meals.

Clinical trials were conducted on volunteers on the basis of the Central military clinical hospital of the Ministry of defense of the Russian Federation, msri of eye diseases Helmholtz, in the Morozov children's clinical hospital.

The results about the Eden clinical and functional studies have led to the conclusion:

allergic reactions and unwanted effects during administration of the drug were noted in any of the cases;

during treatment showed good tolerability;

when receiving "Eye-complex was found to have a positive effect potentiation at repeated courses compared to the BAD "Optometrist".

The main reason for the destruction of the Central region of the retina is the action of sunlight, and especially its most aggressive shortwave (UV, violet and blue) part of the spectrum. The human eye has several levels of protection from excess solar radiation - pigmented iris, narrowing the pupil and, finally the yellow spot is a natural filter, located directly in front of the most sensitive area of the retina. Color and light-absorbing action of the macula is provided by two natural carotenoids selectively accumulating in it - lutein and zeaxanthin.

The human body is unable to synthesize these substances, and they must come from outside.

The solution to this situation could be an increase in consumption of vegetables rich in lutein and zeaxanthin (carrots, spinach, corn, tomatoes, green peas, calendula etc), as well as the creation of pharmaceuticals with the inclusion of these substances.

P is because the methods of treatment of macular degeneration of the retina is unknown, these preventative measures are the only reliable means of combating age-related loss of vision.

Recently appeared dietary supplements that contain lutein derived from marigold flowers. Studies have shown that lutein is well absorbed and stored in the macula, which is why its density can be increased by intake of lutein as a Supplement (Mares-Perlman J.A. et al. // Am. J. Epidemiol. - 2001. - Vol.62. - P.1448-1461).

Despite the importance of lutein in the prevention of macular degeneration important provision of the organism in the first place individuals at risk, and other micronutrients, first of all antioxidants.

Data analysis for prevention of diseases of the eye, caused by activation of free-radical and peroxy processes of cataracts and macular degeneration, shows that the proposed complex showed good therapeutic effect. In addition to lutein, specifically controlling the neutralization of singlet oxygen in the prevention of macular degeneration, and therefore in the maintenance of normal vision operates a balanced set of substances (vegetable component, b vitamins, beta-carotene, trace elements), complementing and reinforcing the action of each other.

1. For the treatment of diseases of the eye, containing blueberries are Sublim the traditional drying, dihydroquercetin, beta-carotene, seleken, characterized in that it additionally contains lutein, vitamin B1B2In6In12and zinc in the following ingredients in 1 capsule, mg:

blueberries freeze-drying282,7
dihydroquercetinof 17.0
beta carotene0,23
selexin0,07
lutein0,75-20,0
vitamin b10,255-10,2
vitamin b2of 0.3 to 12.0
vitamin b6of 0.3 to 12.0
vitamin B120,45-18,0 mcg
zinc1,8-80,0

2. The tool according to claim 1, characterized in that it can be used to improve vision in retinopathy, night blindness, eye fatigue, glaucoma, cataracts.

3. The tool according to claim 1, characterized in that it can be used as a tool for maintenance therapy in the pathology of yellow spots (macular degeneration), and the retina.

4. The tool according to claim 2 or 3, characterized in that the dose for the prevention of these diseases is 1 capsule 3 times a day during meals.

5. The tool according to claim 2 or 3, characterized the eat, what dose as a means for supporting therapy is 2 capsules 3 times a day during meals.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves carrying out tonometry, patient examination in slit lamp light, determining filtration cushion size and relief, carrying out test with sterile air introduced under conjunctiva in operation zone in combination with glycocorticosteroid preparation. Filtration cushion height increasing and air entering the anterior chamber, diuretic drugs are prescribed and preparations inhibiting intraocular fluid secretion. Filtration cushion becoming flat, glycocorticosteroid preparations, enzyme preparations are introduced and antimetabolite is introduced under conjunctiva outside of operation field. Filtration cushion relief being variable and air passes into the anterior chamber, anti-inflammatory therapy, anti-proliferative treatment course, glycocorticosteroid and enzyme preparations are prescribed. Filtration cushion becoming flat, and air does not enter the anterior chamber, gonioscopy is carried out and surgical intervention zones are revised in the cases of open internal fistula and antibiotic of cytostatic activity is to be prescribed. Internal fistula being blocked, laser surgical intervention is carried out. Hypertension being persistent, anti-glaucoma intervention is carried out in another eyeball segment with antibiotic of cytostatic activity being applied.

EFFECT: enhanced effectiveness of treatment selection.

FIELD: organic chemistry, medicine, ophthalmology, pharmacy.

SUBSTANCE: invention relates to novel derivatives of benzo[g]quinoline of the formula (I): as a free base or acid-additive salt used in treatment of glaucoma and myopia, and to a method for their synthesis and a pharmaceutical composition. In compound of the formula (I) each A and B means hydrogen atom (H); X means -CH2; Y means sulfur atom (S); R1 means H or (C1-C4)-alkyl wherein this compound can be in form of a free base or acid-additive salt. Method for synthesis of compound of the formula (I) by claim 1 or its salt involves the conversion step of alkoxy-group in compound of the formula (II): wherein A, B, X, Y and R1 have values given in claim 1; R3 means (C1-C4)-alkyl to hydroxy-group, and conversion of synthesized compounds of the formula (I) to free base or its acid-additive salt.

EFFECT: improved method of synthesis, valuable medicinal properties of compounds and pharmaceutical composition.

7 cl, 1 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves administration of chitosan sponge with square up to 2 cm2 into sub-Tenon's space wherein chitosan sponge shows the deacetylation degree 98%, its molecular mass is 1000 kDa and it comprises 2.8 x 10-9 g of hyaluronic acid, 27.8 x 10-8 g of chondroitinsulfuric acid, 3.06 x 10-11 g of cattle serum growth factor and 7 x 10-9 g of heparin per 1 mm2 of chitosan sponge. Method provides stabilizing visual function, to improving vision and expanding vision field based on enhancing sensitivity of optic nerve as result of blood stream enhancing. Invention can be used in treatment of progressing glaucoma with non-stabilizing functions.

EFFECT: improved method of treatment.

1 tbl, 1 ex

FIELD: medicine, ophthalmology, medicinal biochemistry.

SUBSTANCE: invention relates to manufacturing ophthalmic composition used for reducing intraocular pressure. Invention proposes using inhibitors of glycogen synthase kinase-3. Proposed composition provides reducing intraocular pressure by increasing intraocular liquid efflux and to prevent loss of retina ganglion cells.

EFFECT: valuable medicinal properties of inhibitors.

19 cl, 6 ex

FIELD: medicine.

SUBSTANCE: method involves introducing Mytomycin C metabolite into eyes where compensated and subcompensated intraocular pressure being achieved as a result of maximum hypotensive therapy application. The preparation is introduced 4 weeks in advance before operation in initial and advanced glaucoma stages and 2-3 weeks in advance in cases gone too far. The dose to be introduced is equal to 0.1 ml with concentration equal to 0.15 mg/ml. Additional Mytomycin C injection of the same volume and concentration of 0.2 mg/ml is introduced after having finished the reparative operation.

EFFECT: enhanced effectiveness of treatment; prolonged intraocular pressure stabilization.

1 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves administration of the preparation "Ginkor-Fort" in the dose 1 tablet, 2 times per a day for 2 weeks and after one month break the preparation "Diovenor" is administrated in the dose 1 tablet, once per a day for 2 weeks at the constant instillation of the preparation "Ksalatan" in the dose 1 drop, once time before night. Such schedule of the method provides the stable normalization of intraocular pressure based on improvement of venous orbital and cerebral circulation. Invention is designated for medicinal treatment of glaucoma discirculatory variant.

EFFECT: improved method of treatment.

2 tbl, 1 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: the present innovation deals with medicinal treatment of ischemic variant of primary glaucoma in case of stable normalization of intraocular pressure (IOP) in patients with myopic refraction. For this purpose, it is necessary to carry out electromagnetic impact successively onto cerebral orbital, temporal and occipital areas, carotid sinuses of cervical autonomic plexus, and, also, one should additionally inject gliatilin per 1.0 in combination with instillations of 0.5%-betaxolol solution per 2 drops twice daily into ocular conjunctival cavity. Therapy should last for 10 d at repeating the course once or twice annually. The method provides stable normalization of IOP, improves cerebral and orbital hemodynamics and stabilization of visual functions.

EFFECT: higher efficiency of therapy.

1 ex, 5 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new biologically active derivatives of aminoquinoline and aminopyridine. Invention describes compounds of the general formula (I): wherein R1 means hydrogen atom or direct or branched (C1-C4)-alkyl group; R2 means hydrogen atom or direct or branched (C1-C4)-alkyl group; R3 means hydrogen atom or direct or branched (C1-C4)-alkyl group or phenyl group, thienyl group or furyl group optionally substituted with one or more direct or branched (C1-C4)-alkyl group, direct or branched (C1-C4)-alkoxy-group or halogen atom; R4 and R5 form in common 1,3-butadienyl group optionally substituted with methylenedioxy-group or one or more direct or branched (C1-C4)-alkyl group, direct or branched (C1-C4)-alkoxy-group, hydroxy-group or halogen atom; R6 means hydrogen atom or cyano-group; R7 means hydrogen atom or direct or branched (C1-C4)-alkyl group, phenyl group, benzyl group, thienyl group, or furyl group optionally substituted with methylenedioxy-group or one or more direct or branched (C1-C4)-alkyl group, direct or branched (C1-C4)-alkoxy-group, hydroxy-group, trifluoromethyl group, cyano-group or halogen atom; X means -NH-group, -NR8-group or sulfur atom, or oxygen atom, or sulfo-group, or sulfoxy-group wherein R8 means direct or branched (C1-C4)-alkyl group or (C3-C6)-cycloalkyl group; n = 0, 1 or 2, and their salts. Also, invention describes a method for preparing compounds of the formula (I). a pharmaceutical composition based on thereof, using compounds of the formula (I) as antagonists of A3 receptors for preparing a pharmaceutical composition used in treatment of different diseases (variants), compounds of the formula (IA), (II), (III) and (IV) given in the invention description. Invention provides preparing new compounds possessing the useful biological properties.

EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.

15 cl, 6 tbl, 6 dwg, 172 ex

FIELD: organic chemistry, medicine, ophthalmology, pharmacy.

SUBSTANCE: invention relates to new derivatives of nitrogen-containing heterocyclic compounds of the general formula (I): wherein X1, X2, X3, X4 and X5 mean -CH2 or one of them represents -NH and another X1-X5 represent -CH2; k = 0, 1 or 2; when t = 2, then radicals R1 are similar or different; R1 represents direct or branched (C1-C8)-alkyl or (C1-C8)-alkoxy-group; A means phenyl or pyridinyl; R2 means hydrogen atom (H), hydroxyl, halogen atom, (C1-C6)-alkyl, (C1-C6)-alkoxy-group; n = 0, 1-4; radicals R2 are similar or different, when n > 1; p = 0 or 1-5; Y means -OC(O); Z means -CH, or to their pharmaceutically acceptable salts. Compounds of the formula (I) possess agonistic activity with respect to muscarinic receptors and can be used in medicine as medicinal preparations for treatment of neurodegenerative diseases or diseases associated with increased intraocular pressure.

EFFECT: valuable medicinal properties of derivatives.

6 cl, 1 tbl, 2 dwg, 16 ex

FIELD: organic chemistry, medicine, ophthalmology, pharmacy.

SUBSTANCE: invention relates to new pyranoindazoles of the formula (1): wherein R1 and R2 are chosen independently from hydrogen atom or alkyl group; R3 and R4 represent independently hydrogen atom or alkyl group; R5, R6 and R7 mean hydrogen atom; R8 and R9 mean hydrogen atom, hydroxyl, alkoxy-group, -NR10R11, -OC(=O)NR1R2, -OC(=O)-(C1-C4)-alkyl or alkylthiol; R10 and R11 mean hydrogen atom; A means -(CH2)n, C=O; B means a simple or double bond; n = 0-2; Y means nitrogen atom (N); X means carbon atom C; dotted line means the corresponding simple or double bond. Also, invention relates to a pharmaceutical composition based on compounds of the formula (1), to a method for regulating normal or enhanced intraocular pressure, method for treatment of glaucoma and method for blocking or binding serotonine receptors. Invention provides preparing new pyranoindazoles possessing the valuable pharmaceutical effect.

EFFECT: valuable medicinal properties of compounds and composition.

14 cl, 4 tbl, 22 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes a pharmaceutical composition for oral using as a tablet designated for treatment of bone diseases and some disturbances of calcium metabolism. A table core comprises bisphosphonates or their physiologically safe salts as an active substance. Preferably, the active substance is ibandronic acid. Preferably, a table core comprises 100 mg or 150 mg of bisphosphonates or equivalent amount of their physiologically safe salts. Also, invention describes a method for preparing the composition by addition of a raising agent at granulation step simultaneously with bisphophonate and part of raising agent. Invention provides enhanced stability of tablets in their storage by such parameters as temperature and humidity.

EFFECT: improved and valuable pharmaceutical properties of composition.

16 cl, 2 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes a pharmaceutical composition for oral using as a tablet designated for treatment of bone diseases and some disturbances of calcium metabolism. A table core comprises bisphosphonates or their physiologically safe salts as an active substance. Preferably, the active substance is ibandronic acid. Preferably, a table core comprises 100 mg or 150 mg of bisphosphonates or equivalent amount of their physiologically safe salts. Also, invention describes a method for preparing the composition by addition of a raising agent at granulation step simultaneously with bisphophonate and part of raising agent. Invention provides enhanced stability of tablets in their storage by such parameters as temperature and humidity.

EFFECT: improved and valuable pharmaceutical properties of composition.

16 cl, 2 ex

FIELD: pharmaceutical technology, pharmacy.

SUBSTANCE: invention relates to preparing medicinal formulations as film membranes in aims for providing hemostatic, wound-healing, anti-inflammatory effect in medicinal practice. Membrane comprises furacillin as a medicinal component, chitosan as a film-forming agent and dimethylsulfoxide, aerosil, 98% acetic acid for preparing its 2% solution and water as accessory substances. The novel medicinal membrane possesses the prolonged curative effect. Invention expands region for using the membrane.

EFFECT: valuable medicinal properties of membrane.

7 tbl, 3 dwg, 1 ex

FIELD: pharmaceutical technology, pharmacy.

SUBSTANCE: group of inventions relates to a composition of lectin-containing enteric coating, in particular, for mistletoe extract, and to composition for microcapsules with enteric coating containing lectin as a main component. Granulated composition comprises the following components, g: mannitol as an excipient, 115; Avicel PH 101, 18; calcium disubstituted phosphate, 17; hydroxypropylmethylcellulose, 20 as a binding solution; water, 100 ml; ethyl alcohol, 100 ml; Zein-DR, 25 g as a solution for applying a coating; shellac, 35 g and 80% ethyl alcohol, 180 ml wherein solution for applying a coating is prepared by dissolving 50 weight % of reagent for a coating and 50 weight % of a plasticizing agent. Composition for tableting of lectin-containing microcapsules with enteric coating comprises the following components, PLGA/CH2Cl2, 4 ml; 1% polyvinyl alcohol, 50 ml; Span-80, 2 ml as a surfactant; food oil, 48 ml; 1-4% sodium alginate solution, 8 ml, and 0.02-0.2 M CaCl2 solution, 60 ml. Invention provides solution the problem associated with instability in digestive tract after oral administration that enhances effectiveness of a medicinal agent and effectiveness of treatment in therapeutic institutions.

EFFECT: improved, enhanced and valuable pharmaceutical properties of composition.

4 cl, 3 tbl, 2 dwg, 9 ex

FIELD: pharmaceutical technology, pharmacy.

SUBSTANCE: group of inventions relates to a composition of lectin-containing enteric coating, in particular, for mistletoe extract, and to composition for microcapsules with enteric coating containing lectin as a main component. Granulated composition comprises the following components, g: mannitol as an excipient, 115; Avicel PH 101, 18; calcium disubstituted phosphate, 17; hydroxypropylmethylcellulose, 20 as a binding solution; water, 100 ml; ethyl alcohol, 100 ml; Zein-DR, 25 g as a solution for applying a coating; shellac, 35 g and 80% ethyl alcohol, 180 ml wherein solution for applying a coating is prepared by dissolving 50 weight % of reagent for a coating and 50 weight % of a plasticizing agent. Composition for tableting of lectin-containing microcapsules with enteric coating comprises the following components, PLGA/CH2Cl2, 4 ml; 1% polyvinyl alcohol, 50 ml; Span-80, 2 ml as a surfactant; food oil, 48 ml; 1-4% sodium alginate solution, 8 ml, and 0.02-0.2 M CaCl2 solution, 60 ml. Invention provides solution the problem associated with instability in digestive tract after oral administration that enhances effectiveness of a medicinal agent and effectiveness of treatment in therapeutic institutions.

EFFECT: improved, enhanced and valuable pharmaceutical properties of composition.

4 cl, 3 tbl, 2 dwg, 9 ex

FIELD: medicine, gynecology, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to an anti-estrogenic and anti-proliferative agent used in treatment and prophylaxis of diseases of female reproductive system and represents a tablet covered with envelope and containing indole-3-carbonol and lactose, microcrystalline cellulose, butylhydroxyanisol, modified maize starch, magnesium or calcium stearate as accessory substances, and an enteric coating "AKRILIZ" as envelope. The tablet composition provides the enhanced therapeutic effect, high stability and bioavailability.

EFFECT: improved and valuable medicinal properties of agent.

6 dwg, 3 ex

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: claimed composition represents emulsion from phospholipids in form of liposome with average particle size of 0.2-0.4 mum having membranes with integrated dihydroquercetin flavonoid and wheat germ oil, containing hydrophobic antioxidants such as tocopherols (Vitamin E) and carothenoids. Emulsion water phase contains sodium chloride, water soluble antioxidants such as ascorbic acid (Vitamin C), N-acetyl L-cysteine and sodium benzoate.

EFFECT: effective composition for inhalation with prolonged storage time.

1 tbl, 1 ex

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: claimed composition represents emulsion from phospholipids in form of liposome with average particle size of 0.2-0.4 mum having membranes with integrated dihydroquercetin flavonoid and wheat germ oil, containing hydrophobic antioxidants such as tocopherols (Vitamin E) and carothenoids. Emulsion water phase contains sodium chloride, water soluble antioxidants such as ascorbic acid (Vitamin C), N-acetyl L-cysteine and sodium benzoate.

EFFECT: effective composition for inhalation with prolonged storage time.

1 tbl, 1 ex

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: claimed composition represents emulsion from phospholipids in form of liposome with average particle size of 0.2-0.4 mum having membranes with integrated dihydroquercetin flavonoid and wheat germ oil, containing hydrophobic antioxidants such as tocopherols (Vitamin E) and carothenoids. Emulsion water phase contains sodium chloride, water soluble antioxidants such as ascorbic acid (Vitamin C), N-acetyl L-cysteine and sodium benzoate.

EFFECT: effective composition for inhalation with prolonged storage time.

1 tbl, 1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a novel stable ready formulation of pharmaceutical composition containing VIII factor and can be used in treatment of hemophilia. Invention relates to a solid pharmaceutical composition prepared by lyophilization of an amino acid-free solution and comprising the following components: (a) VIII factor in the concentration 50-10000 IU/ml for human VIII factor or human recombinant VIII factor, or 50-10000 U/ml for swine VIII factor or swine recombinant VIII factor; (b) surfactant in the concentration above critical micellar concentration up to 1% (vol./vol.); (c) calcium chloride; (d) sucrose; (e) sodium chloride; (f) trisodium citrate, and (g) amino acids-free buffer in the concentration 1-50 mM with pH 6-8 before lyophilization and after dissolving in water for injection. Also, invention relates to a liquid pharmaceutical composition prepared after dissolving indicated stable solid pharmaceutical composition in sterile water optionally containing sodium chloride. Invention provides preparing a stable ready formulation of pharmaceutical composition of VIII factor wherein albumin is replaced with other stabilizing agents.

EFFECT: improved and valuable properties of pharmaceutical composition.

25 cl, 3 tbl, 3 ex

FIELD: medicine, in particular balneology and physical therapy.

SUBSTANCE: claimed additive contains dihydroquercetin or mixture of dihydroquercetin and milky whey in ratio from 2:1 to 1:2 as biologically active additive for balneological bath agent. Dalneological bath agent includes base, osmolytically active components such as glycerol and inorganic salts, as well as biologically active additive of plant and/or animal origin, wherein osmolytic activity is 7700-11000 mOsm/l. As biologically active additive of plant and/or animal origin it contains dihydroquercetin or mixture of dihydroquercetin and milky whey in ratio from 2:1 to 1:2 and as the base it contains water and/or concentrated milk in the next component ratio (mass %): glycerol 25.0-30.0; inorganic salts 10.0-15.0; dihydroquercetin or mixture of dihydroquercetin and milky whey 0.2-1.0; and balance: water and/or concentrated milk up to 100 %.

EFFECT: new effective additive for balneological bath agent.

5 cl, 9 ex

Up!